Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huoxiang Zhengqi Oral Liquid for IBS-D with dampness pattern
ChiCTR1900026837Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Nov 2019
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Huoxiang Zhengqi in Diarrhea-predominant irritable bowel syndrome (IBS-D) (3 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Response rate of adequate relief. Started Nov 2019; status: recruiting.
02
Drugs
Huoxiang Zhengqi
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR1900026837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026837.